Cargando…
A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India
Objective Classification of breast cancer into different molecular subtypes has important prognostic and therapeutic implications. The immunohistochemistry surrogate classification has been advocated for this purpose. The primary objective of the present study was to assess the prevalence of the di...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635761/ https://www.ncbi.nlm.nih.gov/pubmed/37969672 http://dx.doi.org/10.1055/s-0043-1761942 |
_version_ | 1785146358002352128 |
---|---|
author | Somal, Puneet Kaur Sancheti, Sankalp Sharma, Aishwarya Sali, Akash Pramod Chaudhary, Debashish Goel, Alok Dora, Tapas Kumar Brar, Rahat Gulia, Ashish Divatia, Jigeeshu |
author_facet | Somal, Puneet Kaur Sancheti, Sankalp Sharma, Aishwarya Sali, Akash Pramod Chaudhary, Debashish Goel, Alok Dora, Tapas Kumar Brar, Rahat Gulia, Ashish Divatia, Jigeeshu |
author_sort | Somal, Puneet Kaur |
collection | PubMed |
description | Objective Classification of breast cancer into different molecular subtypes has important prognostic and therapeutic implications. The immunohistochemistry surrogate classification has been advocated for this purpose. The primary objective of the present study was to assess the prevalence of the different molecular subtypes of invasive breast carcinoma and study the clinicopathological parameters in a tertiary care cancer center in rural North India. Materials and Methods All female patients diagnosed with invasive breast cancer and registered between January 1, 2015, and December 31, 2020, were included. Patients with bilateral cancer, missing information on HER2/ER/PR receptor status, absence of reflex FISH testing after an equivocal score on Her 2 IHC were excluded. The tumors were classified into different molecular subtypes based on IHC expression as follows-luminal A-like (ER- and PR-positive, Her2-negative, Ki67 < 20%), luminal B-like Her2-negative (ER-positive, Her2-negative and any one of the following Ki67% ≥ 20% or PR-negative/low, luminal B-like Her2-positive (ER- and HER2-positive, any Ki67, any PR), Her2-positive (ER- and PR-negative, Her2-positive) and TNBC (ER, PR, Her2-negative). Chi square test was used to compare the clinicopathological parameters between these subtypes. Results A total of 1,625 cases were included. Luminal B-like subtype was the most common (41.72%). The proportion of each subtype was luminal A (15.69%), luminal B Her2-negative (23.93%), luminal B Her2-positive (17.78%), Her2-positive (15.26%), TNBC (27.32%). Majority of the tumors were Grade 3 (75.81%). Nodal metastases were present in 59%. On subanalysis of the luminal type tumors without Her2 expression (luminal A-like and luminal B-like (Her2-negative), luminal A-like tumors presented significantly with a lower grade ( p < 0.001) and more frequent node-negative disease in comparison to luminal B-like (Her2-negative) tumors. In comparison to other subtypes, TNBC tumors were more frequently seen in the premenopausal age group ( p < 0.001) and presented with node-negative disease ( p < 0.001). Conclusion This is one of the largest studies that enumerates the prevalence of various molecular subtypes of breast cancer in North India. Luminal B-like tumors were the most common followed by TNBC. TNBC tumors presented more commonly in premenopausal age group and with node negative disease in comparison to other subtypes. |
format | Online Article Text |
id | pubmed-10635761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106357612023-11-15 A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India Somal, Puneet Kaur Sancheti, Sankalp Sharma, Aishwarya Sali, Akash Pramod Chaudhary, Debashish Goel, Alok Dora, Tapas Kumar Brar, Rahat Gulia, Ashish Divatia, Jigeeshu South Asian J Cancer Objective Classification of breast cancer into different molecular subtypes has important prognostic and therapeutic implications. The immunohistochemistry surrogate classification has been advocated for this purpose. The primary objective of the present study was to assess the prevalence of the different molecular subtypes of invasive breast carcinoma and study the clinicopathological parameters in a tertiary care cancer center in rural North India. Materials and Methods All female patients diagnosed with invasive breast cancer and registered between January 1, 2015, and December 31, 2020, were included. Patients with bilateral cancer, missing information on HER2/ER/PR receptor status, absence of reflex FISH testing after an equivocal score on Her 2 IHC were excluded. The tumors were classified into different molecular subtypes based on IHC expression as follows-luminal A-like (ER- and PR-positive, Her2-negative, Ki67 < 20%), luminal B-like Her2-negative (ER-positive, Her2-negative and any one of the following Ki67% ≥ 20% or PR-negative/low, luminal B-like Her2-positive (ER- and HER2-positive, any Ki67, any PR), Her2-positive (ER- and PR-negative, Her2-positive) and TNBC (ER, PR, Her2-negative). Chi square test was used to compare the clinicopathological parameters between these subtypes. Results A total of 1,625 cases were included. Luminal B-like subtype was the most common (41.72%). The proportion of each subtype was luminal A (15.69%), luminal B Her2-negative (23.93%), luminal B Her2-positive (17.78%), Her2-positive (15.26%), TNBC (27.32%). Majority of the tumors were Grade 3 (75.81%). Nodal metastases were present in 59%. On subanalysis of the luminal type tumors without Her2 expression (luminal A-like and luminal B-like (Her2-negative), luminal A-like tumors presented significantly with a lower grade ( p < 0.001) and more frequent node-negative disease in comparison to luminal B-like (Her2-negative) tumors. In comparison to other subtypes, TNBC tumors were more frequently seen in the premenopausal age group ( p < 0.001) and presented with node-negative disease ( p < 0.001). Conclusion This is one of the largest studies that enumerates the prevalence of various molecular subtypes of breast cancer in North India. Luminal B-like tumors were the most common followed by TNBC. TNBC tumors presented more commonly in premenopausal age group and with node negative disease in comparison to other subtypes. Thieme Medical and Scientific Publishers Pvt. Ltd. 2023-03-09 /pmc/articles/PMC10635761/ /pubmed/37969672 http://dx.doi.org/10.1055/s-0043-1761942 Text en MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Somal, Puneet Kaur Sancheti, Sankalp Sharma, Aishwarya Sali, Akash Pramod Chaudhary, Debashish Goel, Alok Dora, Tapas Kumar Brar, Rahat Gulia, Ashish Divatia, Jigeeshu A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India |
title | A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India |
title_full | A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India |
title_fullStr | A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India |
title_full_unstemmed | A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India |
title_short | A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India |
title_sort | clinicopathological analysis of molecular subtypes of breast cancer using immunohistochemical surrogates: a 6-year institutional experience from a tertiary cancer center in north india |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635761/ https://www.ncbi.nlm.nih.gov/pubmed/37969672 http://dx.doi.org/10.1055/s-0043-1761942 |
work_keys_str_mv | AT somalpuneetkaur aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT sanchetisankalp aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT sharmaaishwarya aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT saliakashpramod aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT chaudharydebashish aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT goelalok aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT doratapaskumar aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT brarrahat aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT guliaashish aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT divatiajigeeshu aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT somalpuneetkaur clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT sanchetisankalp clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT sharmaaishwarya clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT saliakashpramod clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT chaudharydebashish clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT goelalok clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT doratapaskumar clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT brarrahat clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT guliaashish clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia AT divatiajigeeshu clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia |